解放军医学院学报2018，Vol.39Issue(12)：1106-1109,4.DOI:10.3969/j.issn.2095-5227.2018.12.019
PD-1/PD-L1抑制剂疗效相关生物预测标记物的研究进展
Research advances in predictive biomarkers of anti PD-1/PD-L1 immunotherapy
摘要
Abstract
Despite the marked success of applications of PD-1/PD-L1 checkpoint blockades in clinical practice, the efficacy and responsiveness of these agents varies greatly among different tumor types and across individual patients.Therefore, establishment of predictive biomarkers for checkpoint blockades is of great importance to maximize the therapeutic benefits.In this review, we discuss the current progress and challenges of developing predictive biomarkers of immunotherapy responsiveness, aiming to provide directions for future studies.PD-L1 expression is a logical biomarker for the prediction of response to anti-PD- (L) 1 immunotherapies.However, the predictive values of PD-L1 expressions for immunotherapy still remain controversial.Multiplex detecting methods and combined biomarkers may provide new strategies, including tumor mutation burden, some oncogene mutations, like EGFR, ALK, KRAS and STK11.As current evidence of those potential predictors, a consensus and standardization is needed to be established for popularization in future studies.关键词
免疫检查点抑制剂/程序性死亡受体-1/程序性死亡配体-1/生物预测标记物Key words
immune-checkpoint inhibitor/programmed death 1/programmed death ligand 1/biomarker分类
医药卫生引用本文复制引用
董苑梅,焦顺昌..PD-1/PD-L1抑制剂疗效相关生物预测标记物的研究进展[J].解放军医学院学报,2018,39(12):1106-1109,4.基金项目
国家重点研发计划精准医学研究专项(2016YFC0905402) （2016YFC0905402）
